Ionis Cuts TRYNGOLZA 2026 Guidance to ~$50M as Q3 Loss Widens
IONS is trading near its 52-week low of $27.75 (12% above the low) on elevated volume (5.6× avg).
Summary
Ionis posted Q3 2026 revenue of $243 million, up 54.8% year over year, but the net loss widened to $110 million, or $0.66 a share. The bigger problem is TRYNGOLZA: management cut 2026 sales guidance to about $50 million, a steep markdown from the roughly $100 million figure circulated with yesterday's release, while revenue and cash outlooks were left unchanged. The pipeline readout was mixed — sefaxersen and ulefnersen hit their Phase 3 goals, but pelacarsen and eplontersen missed. HIBSAGO is the offset, winning approvals in the U.S., Japan and Canada and triggering a $30 million milestone, with royalties to follow as the global launch begins. The analyst consensus stays Buy, though the average 12-month price target slipped to $83.38 from $84.90 as several firms trimmed. Next specific checkpoint: the EU's final decision on TRYNGOLZA for severe hypertriglyceridemia, expected in Q4 2026.
At the time of this announcement, IONS was trading at $31.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $27.75 to $86.74. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.